Comparative analysis of prostate‐specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy …

…, P Kupelian, WR Lee, S Machtens, J Mayadev… - BJU …, 2012 - Wiley Online Library
Comparative analysis of prostateâ•’specific antigen free survival outcomes for patients with
low, intermediate and high ris Page 1 © 2012 THE AUTHORS 2 2 BJU INTERNATIONAL © …

Radiation therapy for cervical cancer: executive summary of an ASTRO clinical practice guideline

…, M Kamrava, E Leung, LL Lin, JS Mayadev… - Practical radiation …, 2020 - Elsevier
Purpose This guideline reviews the evidence and provides recommendations for the indications
and appropriate techniques of radiation therapy (RT) in the treatment of nonmetastatic …

Advances in immunotherapy for cervical cancer: recent developments and future directions

…, NV Kotha, C Williamson, J Mayadev - International Journal of …, 2022 - ijgc.bmj.com
There is an unmet need for novel therapies to improve clinical outcomes for patients with
locally advanced, recurrent, or metastatic cervical cancer. Most cases of cervical cancer are …

Global challenges of radiotherapy for the treatment of locally advanced cervical cancer

JS Mayadev, G Ke, U Mahantshetty… - International Journal of …, 2022 - ijgc.bmj.com
Cervical cancer represents a significant portion of the global cancer burden for women, with
low- and middle-income countries carrying the bulk of this burden. Additionally, underserved …

Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial

…, A Lloyd, H Dry, AT Nunes, J Mayadev - The lancet …, 2023 - thelancet.com
Background Concurrent chemoradiotherapy has been the standard of care for locally advanced
cervical cancer for over 20 years; however, 30–40% of treated patients have recurrence …

Immunotherapy with radiotherapy and chemoradiotherapy for cervical cancer

…, LK Mell, AB Sharabi, M McHale, JS Mayadev - Seminars in Radiation …, 2020 - Elsevier
Outcomes for women with node-positive, recurrent, and metastatic cervical cancer remain
poor. Persistent infection by the human papilloma virus is related to disordered interactions …

Sequential ipilimumab after chemoradiotherapy in curative-intent treatment of patients with node-positive cervical cancer

JS Mayadev, D Enserro, YG Lin, DM Da Silva… - JAMA …, 2020 - jamanetwork.com
Importance Despite standard chemoradiotherapy (CRT), most women with lymph node (LN)–positive
cervical cancer experience disease recurrence. Immunotherapy is being …

CALLA: efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical …

J Mayadev, AT Nunes, M Li, M Marcovitz… - International Journal of …, 2020 - ijgc.bmj.com
Background Concurrent chemoradiotherapy is the standard of care for locally advanced
cervical cancer. Concurrent chemoradiotherapy with programmed blockade of the cell death-1/…

Role of postmastectomy radiation after neoadjuvant chemotherapy in stage II-III breast cancer

…, JP Einck, DN Kim, S McCloskey, J Mayadev… - International Journal of …, 2012 - Elsevier
PURPOSE: To identify a cohort of women treated with neoadjuvant chemotherapy and
mastectomy for whom postmastectomy radiation therapy (PMRT) may be omitted according to the …

Immunotherapy and radiation therapy sequencing: State of the data on timing, efficacy, and safety

…, AB Sharabi, BA Dyer, LK Mell, JS Mayadev - Cancer, 2021 - Wiley Online Library
Radiation therapy exerts a tumoricidal local effect as well as both local and systemic
immunomodulation. Immune checkpoint blockade has become a widely used treatment modality …